domingo, 6 de noviembre de 2016

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. - PubMed - NCBI

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. - PubMed - NCBI

 2016 Nov;11(11):1901-1911. doi: 10.1016/j.jtho.2016.06.025. Epub 2016 Jul 20.

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.

Toki MI1, Carvajal-Hausdorf DE1, Altan M2, McLaughlin J2, Henick B2, Schalper KA3, Syrigos KN4, Rimm DL5.

Abstract

INTRODUCTION:

EGFR is a therapeutic target in NSCLC for EGFR-mutant patients. Proximity ligation assay (PLA) is a method to detect functional signaling associated protein complexes. Growth factor receptor bound protein 2 (GRB2) is an adaptor protein that binds to the phosphorylated residues of active EGFR. Interaction of EGFR and GRB2 correlates with active EGFR signaling and leads to activation of the MAPK/ERK pathway.

METHODS:

A PLA developed to detect EGFR-GRB2 interaction was measured by quantitative immunofluorescence using Automated Quantitative Analysis technology. EGFR pathway activation was assessed in patients with NSCLC with different mutation status along with overall EGFR expression. Additionally, the PLA to detect EGFR-GRB2 interaction was evaluated as a prognostic marker in two cohorts of patients with lung adenocarcinoma.

RESULTS:

The PLA to detect EGFR-GRB2 interaction was unrelated to overall EGFR expression or mutation in a series of patients with NSCLC with known mutation status. EGFR-mutant (p = 0.04) and EGFR/KRAS wild-type tumors (p = 0.0049) had significantly higher EGFR pathway activation compared with KRAS-mutant cases, with no significant difference shown between mutation sites. In two series of patients with lung adenocarcinoma, the PLA to detect EGFR-GRB2 interaction was independently associated with longer survival (hazard ratio = 0.46, 95% confidence interval: 0.2-0.78, p = 0.0085 and hazard ratio = 0.48, 95% confidence interval: 0.2-0.85, p = 0.017). Total EGFR protein expression alone was not correlated with outcome.

CONCLUSIONS:

EGFR colocalization with GRB2 as assessed by PLA is not correlated with EGFR expression levels or mutation status, defining a patient group that may show EGFR pathway activation, as illustrated by its prognostic value. Future studies may determine whether this group is more likely to respond to EGFR-targeted therapies.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

Adenocarcinoma; EGFR; GRB2; NSCLC; Proximity ligation assay; Quantitative immunofluorescence

PMID:
 
27449805
 
PMCID:
 
PMC5075503
 [Available on 2017-11-01]
 
DOI:
 
10.1016/j.jtho.2016.06.025

[PubMed - in process]


Public Health Genomics Knowledge Base (v1.2)

Genomics & Health Impact Update banner with DNA in background

x ray of a lung

LUNG CANCER




Last Updated: Nov 02, 2016

CDC Resources with and image of DNA

Seletced Insights & Reviews with various images of researchers in labortory environments

Epidemiology with an image of a crowd of people with a double helix

Translational Research with two images of people talking to a genetic counselor and an image of a hand with wrapped sequecing around it

Evidence Synthesis with an image of sequencing and a double helix

Practice & Implementation with images of people taking to a doctor and a nurse examining a child

Relevant Resources

Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)